Abstract
gamma-Secretase inhibitors have been shown to reduce the production of beta-amyloid, a component of the plaques that are found in brains of patients with Alzheimer's disease. A novel series of heterocyclic sulfonamide gamma-secretase inhibitors that reduce beta-amyloid levels in cells is reported. Several examples of compounds within this series demonstrate a higher propensity to inhibit the processing of amyloid precursor protein compared to Notch, an alternative gamma-secretase substrate.
MeSH terms
-
Alzheimer Disease / drug therapy*
-
Amyloid Precursor Protein Secretases / antagonists & inhibitors*
-
Amyloid Precursor Protein Secretases / metabolism*
-
Amyloid beta-Peptides / antagonists & inhibitors
-
Amyloid beta-Peptides / metabolism
-
Animals
-
CHO Cells
-
Cricetinae
-
Cricetulus
-
Heterocyclic Compounds / chemical synthesis
-
Heterocyclic Compounds / chemistry*
-
Heterocyclic Compounds / pharmacology*
-
Humans
-
Molecular Structure
-
Protein Binding
-
Receptors, Notch / metabolism
-
Structure-Activity Relationship
-
Sulfonamides / chemical synthesis
-
Sulfonamides / chemistry*
-
Sulfonamides / pharmacology*
Substances
-
Amyloid beta-Peptides
-
Heterocyclic Compounds
-
Receptors, Notch
-
Sulfonamides
-
Amyloid Precursor Protein Secretases